TEPMETKO
Peaktepotinib hydrochloride
NDAORALTABLETPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEPMETKO (tepotinib hydrochloride) is an oral tyrosine kinase inhibitor approved by the FDA on February 3, 2021. It is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. The drug works by selectively inhibiting MET receptor signaling, a key driver of cancer progression in this patient subset. TEPMETKO addresses a defined genomic niche within lung cancer treatment, targeting a specific molecular alteration rather than competing across broad oncology categories.
$0.0BPart D
3.9 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~4 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.